NOVEL MAGNESIUM-SERINATE COMPOUND AND USE THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 4, 2021
app pub date -
Feb 12, 2019
filing date -
Aug 23, 2018
priority date (Note) -
Published
status (Latency Note)
![]() |
A preliminary load of PAIR data current through [] has been loaded. Any more recent PAIR data will be loaded within twenty-four hours. |
PAIR data current through []
A preliminary load of cached data will be loaded soon.
Any more recent PAIR data will be loaded within twenty-four hours.
![]() |
Next PAIR Update Scheduled on [ ] |

Importance

US Family Size
|
Non-US Coverage
|
Abstract
The present invention relates to a novel magnesium-serinate compound and the use thereof, and more particularly, to a novel magnesium-serinate compound in which a magnesium atom is chelated to L-serine, and the pharmaceutical use thereof against central nervous system diseases or the like. It was confirmed that the novel magnesium-serinate composition obtained by the production method of the present invention consisted of about 10% magnesium and about 90% serine, as determined by instrumental analysis, was solubilized at a concentration of about 500 mg/ml in water at room temperature at a pH of 6.0 to 10.0, was maintained in an aqueous solution state without forming a precipitate, and was also solubilized at a concentration of about 500 mg/ml in phosphate-buffered saline (PBS) solution at room temperature without forming a precipitate. Thus, the novel magnesium-serinate composition has properties suitable for administration orally or by injection to the human body. In addition, the compound activates mitochondrial function and neuronal cell proliferation by increasing the oxygen consumption rate of mitochondria, and exhibits a neuronal protective effect of inhibiting neuronal cell death resulting from mitochondrial membrane potential damage and/or endoplasmic reticulum stress caused by oxidative stress, and exhibits improved blood-brain barrier permeability. Therefore, the compound has an excellent effect on the prevention, treatment and alleviation of central nervous system diseases such as cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, and thus is a highly useful invention in the pharmaceutical industry, etc.
First Claim
all claims..Other Claims data not available
Family

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Patent Owner(s)
Patent Owner | Address | |
---|---|---|
ASTROGEN CO LTD | 313-HO 47 GYEONGDAE-RO 17-GIL BUK-GU DAEGU 41566 |
International Classification(s)

- 2019 Application Filing Year
- C07F Class
- 1431 Applications Filed
- 861 Patents Issued To-Date
- 60.17 % Issued To-Date
Inventor(s)
Inventor Name | Address | # of filed Patents | Total Citations |
---|---|---|---|
Jo, Young Kyoung | Daegu, KR | 2 | 0 |
# of filed Patents : 2 Total Citations : 0 | |||
Jun, Do Youn | Gyeongsangbuk-do, KR | 2 | 0 |
# of filed Patents : 2 Total Citations : 0 | |||
Kim, Min Joo | Daegu, KR | 67 | 750 |
# of filed Patents : 67 Total Citations : 750 | |||
Kim, Young Ho | Gyeongsangbuk-do, KR | 253 | 3236 |
# of filed Patents : 253 Total Citations : 3236 | |||
Lee, Min Yong | Gyeongsangbuk-do, KR | 63 | 158 |
# of filed Patents : 63 Total Citations : 158 | |||
Seo, Min Sook | Daegu, KR | 1 | 0 |
# of filed Patents : 1 Total Citations : 0 | |||
Whang, Su-Kyeong | Daegu, KR | 2 | 0 |
# of filed Patents : 2 Total Citations : 0 |
Cited Art Landscape
- No Cited Art to Display

Patent Citation Ranking
- 0 Citation Count
- C07F Class
- 0 % this patent is cited more than
- 4 Age
Forward Cite Landscape
- No Forward Cites to Display

Maintenance Fees
Fee | Large entity fee | small entity fee | micro entity fee | due date |
---|---|---|---|---|
3.5 Year Payment | $1600.00 | $800.00 | $400.00 | May 4, 2025 |
7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | May 4, 2029 |
11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | May 4, 2033 |
Fee | Large entity fee | small entity fee | micro entity fee |
---|---|---|---|
Surcharge - 3.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
Surcharge - 7.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |
Full Text

Legal Events
- No Legal Status data available.

Matter Detail

Renewals Detail
